[Form 4] Abbott Laboratories Insider Trading Activity
Rhea-AI Filing Summary
Abbott Laboratories (ABT) insider transaction: Philip P. Boudreau, Abbott's EVP and CFO, sold 387 common shares at $132.66 per share in a transaction recorded on 09/01/2025, reducing his direct holdings to 50,616 shares. He also reports indirect beneficial ownership of 363 shares held in a Profit Sharing Trust. The filing is signed by an attorney-in-fact on behalf of Mr. Boudreau.
Positive
- Reporting is complete and compliant with Section 16 requirements, including transaction code and holdings after the sale.
- Substantial retained direct ownership of 50,616 shares indicates continued alignment with shareholders.
Negative
- Insider sold 387 shares, a disposition that reduced direct holdings (sale price reported at $132.66 per share).
Insights
TL;DR: Small, routine insider sale; remaining direct holdings remain material for alignment with shareholders.
This sale of 387 shares represents a de minimis disposition relative to total direct holdings of 50,616 shares, suggesting the transaction is likely a routine liquidity event rather than a change in confidence in the company. The report also notes a small indirect holding in a Profit Sharing Trust. No derivative transactions or other material changes to compensation structure are disclosed.
TL;DR: Disclosure is complete and follows Section 16 reporting norms; transaction size is immaterial to governance stance.
The Form 4 identifies the reporting person, relationship to the issuer, transaction code and price, and residual holdings, and includes an explanatory note about the trust balance. The signature is provided via attorney-in-fact as permitted. There are no indications of coordinated sales, option exercises, or other governance events in this filing.